Otamixaban (CAS 193153-04-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

About the Market

Otamixaban is a hematological drug used to treat and prevent thromboembolic disorders. It is a direct factor Xa inhibitor, meaning it works by blocking the action of factor Xa, an enzyme involved in the clotting process. It is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and to treat and prevent deep vein thrombosis and pulmonary embolism. It is also used to reduce the risk of recurrent deep vein thrombosis and pulmonary embolism in patients who have already been treated with a parenteral anticoagulant. Otamixaban is available in both oral and injectable forms, and is typically prescribed in combination with other anticoagulants. It is generally well-tolerated, with the most common side effects being bleeding and anemia. The otamixaban market is a growing segment of the hematological drugs market. It is expected to benefit from the increasing prevalence of thromboembolic disorders, as well as the growing demand for more effective and safer anticoagulants. Some of the major companies in the otamixaban market include Bristol-Myers Squibb, Daiichi Sankyo, Pfizer, and Sanofi. Show Less Read more